Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity
The findings establish <b>LX-191</b> as a promising flavone-based, non-<b>BPTES</b> lead for GLS1 inhibition, exhibiting multi-pathway antitumor activity both <i>in vitro</i> and <i>in vivo</i>. This work provides a tractable lead compound for the development of next-generation GLS1 therapeutics.
Authors
- Tizhi Wu
- Junmu Wang (ORCID: https://orcid.org/0000-0002-6206-1920)
- Cheng Tang (ORCID: https://orcid.org/0000-0002-5783-9873)
- Yibing Wu (ORCID: https://orcid.org/0000-0003-4168-0295)
- Xiaoming Xu (ORCID: https://orcid.org/0000-0003-4779-1316)
- Xiaoyu Zhang (ORCID: https://orcid.org/0000-0002-1752-5482)
- Jinlei Bian
- Hongxi Wu
- Zhixia Qiu
- Yucheng Tian
- Zhiyu Li
- Xuhong Li
- Yan Liang
Institutions
- China Pharmaceutical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Future Medicinal Chemistry
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1080/17568919.2026.2642584
- Primary Topic
- Flavonoids in Medical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00